Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)

BACKGROUND: S-1, an oral fluoropyrimidine, plus cisplatin (SP) is a standard regimen for advanced gastric cancer (AGC) in East Asia. To date, no studies have evaluated the efficacy and safety of trastuzumab combined with SP in patients with human epidermal growth factor receptor type 2 (HER2)-positi...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Kurokawa, Y, Sugimoto, N, Miwa, H, Tsuda, M, Nishina, S, Okuda, H, Imamura, H, Gamoh, M, Sakai, D, Shimokawa, T, Komatsu, Y, Doki, Y, Tsujinaka, T, Furukawa, H
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2014
Предметы:
Clinical Study
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3950868/
https://ncbi.nlm.nih.gov/pubmed/24473399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.18
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы